GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
- Home
- Targets
- Ion channels
- Voltage-gated ion channels
- Potassium channels
- Calcium- and sodium-activated potassium channels (KCa, KNa)
Calcium- and sodium-activated potassium channels (KCa, KNa) C
Unless otherwise stated all data on this page refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).
Overview
Show »« Hide
More detailed introduction 
Calcium- and sodium- activated potassium channels are members of the 6TM family of K channels which comprises the voltage-gated KV subfamilies, including the KCNQ subfamily, the EAG subfamily (which includes hERG channels), the Ca2+-activated Slo subfamily (actually with 6 or 7TM) and the Ca2+- and Na+-activated SK subfamily (nomenclature as agreed by the NC-IUPHAR Subcommittee on Calcium- and sodium-activated potassium channels [31]). As for the 2TM family, the pore-forming a subunits form tetramers and heteromeric channels may be formed within subfamilies (e.g. KV1.1 with KV1.2; KCNQ2 with KCNQ3).
Channels and Subunits
Targets of relevance to immunopharmacology are highlighted in blue
|
KCa1.1 C
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||||||||||||||||||||||||||
|
KCa2.1 C
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||||||||||||||||||||||||||
|
KCa2.2 C
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||||||||||||||||||||||||||
|
KCa2.3 C
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||||||||||||||||||||||||||
|
KCa3.1
C
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||||||||||||||||||||||||||
|
KNa1.1 C
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||||||||||||||||||||||||||
|
KNa1.2 C
Show summary »« Hide summary
More detailed page
|
|||||||||||||||||||||||||||||||||||||||||||||||
|
KCa5.1 C
Show summary »« Hide summary
More detailed page
|
Further reading
* Key recommended reading is highlighted with an asterisk
* Brown BM, Shim H, Christophersen P, Wulff H. (2020) Pharmacology of Small- and Intermediate-Conductance Calcium-Activated Potassium Channels. Annu Rev Pharmacol Toxicol, 60: 219-240. [PMID:31337271]
* Dopico AM, Bukiya AN, Jaggar JH. (2018) Calcium- and voltage-gated BK channels in vascular smooth muscle. Pflugers Arch, 470 (9): 1271-1289. [PMID:29748711]
* Kaczmarek LK, Aldrich RW, Chandy KG, Grissmer S, Wei AD, Wulff H. (2017) International Union of Basic and Clinical Pharmacology. C. Nomenclature and Properties of Calcium-Activated and Sodium-Activated Potassium Channels. Pharmacol Rev, 69 (1): 1-11. [PMID:28267675]
* Kshatri AS, Gonzalez-Hernandez A, Giraldez T. (2018) Physiological Roles and Therapeutic Potential of Ca2+ Activated Potassium Channels in the Nervous System. Front Mol Neurosci, 11: 258. [PMID:30104956]
References
1. Asano S, Bratz IN, Berwick ZC, Fancher IS, Tune JD, Dick GM. (2012) Penitrem A as a tool for understanding the role of large conductance Ca(2+)/voltage-sensitive K(+) channels in vascular function. J Pharmacol Exp Ther, 342 (2): 453-60. [PMID:22580348]
2. Barfod ET, Moore AL, Lidofsky SD. (2001) Cloning and functional expression of a liver isoform of the small conductance Ca2+-activated K+ channel SK3. Am J Physiol, Cell Physiol, 280 (4): C836-42. [PMID:11245600]
3. Bentzen BH, Bomholtz SH, Simó-Vicens R, Folkersen L, Abildgaard L, Speerschneider T, Muthukumarasamy KM, Edvardsson N, Sørensen US, Grunnet M et al.. (2020) Mechanisms of Action of the KCa2-Negative Modulator AP30663, a Novel Compound in Development for Treatment of Atrial Fibrillation in Man. Front Pharmacol, 11: 610. [PMID:32477117]
4. Bentzen BH, Nardi A, Calloe K, Madsen LS, Olesen SP, Grunnet M. (2007) The small molecule NS11021 is a potent and specific activator of Ca2+-activated big-conductance K+ channels. Mol Pharmacol, 72 (4): 1033-44. [PMID:17636045]
5. Bhattacharjee A, Joiner WJ, Wu M, Yang Y, Sigworth FJ, Kaczmarek LK. (2003) Slick (Slo2.1), a rapidly-gating sodium-activated potassium channel inhibited by ATP. J Neurosci, 23 (37): 11681-91. [PMID:14684870]
6. Biton B, Sethuramanujam S, Picchione KE, Bhattacharjee A, Khessibi N, Chesney F, Lanneau C, Curet O, Avenet P. (2012) The antipsychotic drug loxapine is an opener of the sodium-activated potassium channel slack (Slo2.2). J Pharmacol Exp Ther, 340 (3): 706-15. [PMID:22171093]
7. Blanc E, Romi-Lebrun R, Bornet O, Nakajima T, Darbon H. (1998) Solution structure of two new toxins from the venom of the Chinese scorpion Buthus martensi Karsch blockers of potassium channels. Biochemistry, 37 (36): 12412-8. [PMID:9730813]
8. Castle NA, London DO, Creech C, Fajloun Z, Stocker JW, Sabatier JM. (2003) Maurotoxin: a potent inhibitor of intermediate conductance Ca2+-activated potassium channels. Mol Pharmacol, 63 (2): 409-18. [PMID:12527813]
9. Church TW, Weatherall KL, Corrêa SA, Prole DL, Brown JT, Marrion NV. (2015) Preferential assembly of heteromeric small conductance calcium-activated potassium channels. Eur J Neurosci, 41 (3): 305-15. [PMID:25421315]
10. Coleman N, Brown BM, Oliván-Viguera A, Singh V, Olmstead MM, Valero MS, Köhler R, Wulff H. (2014) New positive Ca2+-activated K+ channel gating modulators with selectivity for KCa3.1. Mol Pharmacol, 86 (3): 342-57. [PMID:24958817]
11. Crest M, Jacquet G, Gola M, Zerrouk H, Benslimane A, Rochat H, Mansuelle P, Martin-Eauclaire MF. (1992) Kaliotoxin, a novel peptidyl inhibitor of neuronal BK-type Ca(2+)-activated K+ channels characterized from Androctonus mauretanicus mauretanicus venom. J Biol Chem, 267 (3): 1640-7. [PMID:1730708]
12. Dai L, Garg V, Sanguinetti MC. (2010) Activation of Slo2.1 channels by niflumic acid. J Gen Physiol, 135 (3): 275-95. [PMID:20176855]
13. Diness JG, Skibsbye L, Simó-Vicens R, Santos JL, Lundegaard P, Citerni C, Sauter DRP, Bomholtz SH, Svendsen JH, Olesen SP et al.. (2017) Termination of Vernakalant-Resistant Atrial Fibrillation by Inhibition of Small-Conductance Ca2+-Activated K+ Channels in Pigs. Circ Arrhythm Electrophysiol, 10 (10): e005125. [PMID:29018164]
14. Fanger CM, Rauer H, Neben AL, Miller MJ, Rauer H, Wulff H, Rosa JC, Ganellin CR, Chandy KG, Cahalan MD. (2001) Calcium-activated potassium channels sustain calcium signaling in T lymphocytes. Selective blockers and manipulated channel expression levels. J Biol Chem, 276 (15): 12249-56. [PMID:11278890]
15. Galvez A, Gimenez-Gallego G, Reuben JP, Roy-Contancin L, Feigenbaum P, Kaczorowski GJ, Garcia ML. (1990) Purification and characterization of a unique, potent, peptidyl probe for the high conductance calcium-activated potassium channel from venom of the scorpion Buthus tamulus. J Biol Chem, 265 (19): 11083-90. [PMID:1694175]
16. Garcia ML, Knaus HG, Munujos P, Slaughter RS, Kaczorowski GJ. (1995) Charybdotoxin and its effects on potassium channels. Am J Physiol, 269 (1 Pt 1): C1-10. [PMID:7543240]
17. Garcia-Valdes J, Zamudio FZ, Toro L, Possani LD, Possan LD. (2001) Slotoxin, alphaKTx1.11, a new scorpion peptide blocker of MaxiK channels that differentiates between alpha and alpha+beta (beta1 or beta4) complexes. FEBS Lett, 505 (3): 369-73. [PMID:11576530]
18. Garg P, Sanguinetti MC. (2012) Structure-activity relationship of fenamates as Slo2.1 channel activators. Mol Pharmacol, 82 (5): 795-802. [PMID:22851714]
19. Giangiacomo KM, Kamassah A, Harris G, McManus OB. (1998) Mechanism of maxi-K channel activation by dehydrosoyasaponin-I. J Gen Physiol, 112 (4): 485-501. [PMID:9758866]
20. Griffin AM, Kahlig KM, Hatch RJ, Hughes ZA, Chapman ML, Antonio B, Marron BE, Wittmann M, Martinez-Botella G. (2021) Discovery of the First Orally Available, Selective KNa1.1 Inhibitor: In Vitro and In Vivo Activity of an Oxadiazole Series. ACS Med Chem Lett, 12 (4): 593-602. [PMID:33859800]
21. Higham J, Sahu G, Wazen RM, Colarusso P, Gregorie A, Harvey BSJ, Goudswaard L, Varley G, Sheppard DN, Turner RW et al.. (2019) Preferred Formation of Heteromeric Channels between Coexpressed SK1 and IKCa Channel Subunits Provides a Unique Pharmacological Profile of Ca2+-Activated Potassium Channels. Mol Pharmacol, 96 (1): 115-126. [PMID:31048549]
22. Holst AG, Tomcsányi J, Vestbjerg B, Grunnet M, Sørensen US, Diness JG, Bentzen BH, Edvardsson N, Hohnloser SH, Bhatt DL et al.. (2024) Inhibition of the KCa2 potassium channel in atrial fibrillation: a randomized phase 2 trial. Nat Med, 30 (1): 106-111. [PMID:38092897]
23. Hosseini R, Benton DC, Dunn PM, Jenkinson DH, Moss GW. (2001) SK3 is an important component of K(+) channels mediating the afterhyperpolarization in cultured rat SCG neurones. J Physiol (Lond.), 535 (Pt 2): 323-34. [PMID:11533126]
24. Hougaard C, Eriksen BL, Jørgensen S, Johansen TH, Dyhring T, Madsen LS, Strøbaek D, Christophersen P. (2007) Selective positive modulation of the SK3 and SK2 subtypes of small conductance Ca2+-activated K+ channels. Br J Pharmacol, 151 (5): 655-65. [PMID:17486140]
25. Hougaard C, Hammami S, Eriksen BL, Sørensen US, Jensen ML, Strøbæk D, Christophersen P. (2012) Evidence for a common pharmacological interaction site on K(Ca)2 channels providing both selective activation and selective inhibition of the human K(Ca)2.1 subtype. Mol Pharmacol, 81 (2): 210-9. [PMID:22046005]
26. Iraci N, Carotenuto L, Ciaglia T, Belperio G, Di Matteo F, Mosca I, Carleo G, Giovanna Basilicata M, Ambrosino P, Turcio R et al.. (2024) In Silico Assisted Identification, Synthesis, and In Vitro Pharmacological Characterization of Potent and Selective Blockers of the Epilepsy-Associated KCNT1 Channel. J Med Chem, 67 (11): 9124-9149. [PMID:38782404]
27. Jensen BS. (2002) BMS-204352: a potassium channel opener developed for the treatment of stroke. CNS Drug Rev, 8 (4): 353-60. [PMID:12481191]
28. Jensen BS, Strobaek D, Christophersen P, Jorgensen TD, Hansen C, Silahtaroglu A, Olesen SP, Ahring PK. (1998) Characterization of the cloned human intermediate-conductance Ca2+-activated K+ channel. Am J Physiol, 275 (3): C848-56. [PMID:9730970]
29. Joiner WJ, Wang LY, Tang MD, Kaczmarek LK. (1997) hSK4, a member of a novel subfamily of calcium-activated potassium channels. Proc Natl Acad Sci USA, 94 (20): 11013-8. [PMID:9380751]
30. Jäger H, Adelman JP, Grissmer S. (2000) SK2 encodes the apamin-sensitive Ca(2+)-activated K(+) channels in the human leukemic T cell line, Jurkat. FEBS Lett, 469 (2-3): 196-202. [PMID:10713270]
31. Kaczmarek LK, Aldrich RW, Chandy KG, Grissmer S, Wei AD, Wulff H. (2017) International Union of Basic and Clinical Pharmacology. C. Nomenclature and Properties of Calcium-Activated and Sodium-Activated Potassium Channels. Pharmacol Rev, 69 (1): 1-11. [PMID:28267675]
32. Kasumu AW, Hougaard C, Rode F, Jacobsen TA, Sabatier JM, Eriksen BL, Strøbæk D, Liang X, Egorova P, Vorontsova D et al.. (2012) Selective positive modulator of calcium-activated potassium channels exerts beneficial effects in a mouse model of spinocerebellar ataxia type 2. Chem Biol, 19 (10): 1340-53. [PMID:23102227]
33. Kuzmenkov AI, Peigneur S, Nasburg JA, Mineev KS, Nikolaev MV, Pinheiro-Junior EL, Arseniev AS, Wulff H, Tytgat J, Vassilevski AA. (2022) Apamin structure and pharmacology revisited. Front Pharmacol, 13: 977440. [PMID:36188602]
34. Lee K, Rowe IC, Ashford ML. (1995) NS 1619 activates BKCa channel activity in rat cortical neurones. Eur J Pharmacol, 280 (2): 215-9. [PMID:7589189]
35. Lucchesi K, Ravindran A, Young H, Moczydlowski E. (1989) Analysis of the blocking activity of charybdotoxin homologs and iodinated derivatives against Ca2+-activated K+ channels. J Membr Biol, 109 (3): 269-81. [PMID:2477548]
36. Lyon M, Li P, Ferreira JJ, Lazarenko RM, Kharade SV, Kramer M, McClenahan SJ, Days E, Bauer JA, Spitznagel BD et al.. (2023) A selective inhibitor of the sperm-specific potassium channel SLO3 impairs human sperm function. Proc Natl Acad Sci U S A, 120 (4): e2212338120. [PMID:36649421]
37. Marshall DL, Vatanpour H, Harvey AL, Boyot P, Pinkasfeld S, Doljansky Y, Bouet F, Ménez A. (1994) Neuromuscular effects of some potassium channel blocking toxins from the venom of the scorpion Leiurus quinquestriatus hebreus. Toxicon, 32 (11): 1433-43. [PMID:7533951]
38. Molinari EJ, Sullivan JP, Wan Y, Brioni JD, Gopalakrishnan M. (2000) Characterization and modulation of [125I]iberiotoxin-D19Y/Y36F binding in the guinea-pig urinary bladder. Eur J Pharmacol, 388 (2): 155-61. [PMID:10666507]
39. Nam YW, Im D, Garcia ASC, Tringides ML, Nguyen HM, Liu Y, Orfali R, Ramanishka A, Pintilie G, Su CC et al.. (2025) Cryo-EM structures of the small-conductance Ca2+-activated KCa2.2 channel. Nat Commun, 16 (1): 3690. [PMID:40246884]
40. Nausch B, Rode F, Jørgensen S, Nardi A, Korsgaard MP, Hougaard C, Bonev AD, Brown WD, Dyhring T, Strøbæk D et al.. (2014) NS19504: a novel BK channel activator with relaxing effect on bladder smooth muscle spontaneous phasic contractions. J Pharmacol Exp Ther, 350 (3): 520-30. [PMID:24951278]
41. Novello JC, Arantes EC, Varanda WA, Oliveira B, Giglio JR, Marangoni S. (1999) TsTX-IV, a short chain four-disulfide-bridged neurotoxin from Tityus serrulatus venom which acts on Ca2+-activated K+ channels. Toxicon, 37 (4): 651-60. [PMID:10082164]
42. Olesen SP, Munch E, Moldt P, Drejer J. (1994) Selective activation of Ca(2+)-dependent K+ channels by novel benzimidazolone. Eur J Pharmacol, 251 (1): 53-9. [PMID:8137869]
43. Ong ST, Nam YW, Nasburg JA, Ramanishka A, Ng XR, Zhuang Z, Goay SSM, Nguyen HM, Singh L, Singh V et al.. (2025) Design and structural basis of selective 1,4-dihydropyridine inhibitors of the calcium-activated potassium channel KCa3.1. Proc Natl Acad Sci U S A, 122 (18): e2425494122. [PMID:40294255]
44. Pedarzani P, McCutcheon JE, Rogge G, Jensen BS, Christophersen P, Hougaard C, Strøbaek D, Stocker M. (2005) Specific enhancement of SK channel activity selectively potentiates the afterhyperpolarizing current I(AHP) and modulates the firing properties of hippocampal pyramidal neurons. J Biol Chem, 280 (50): 41404-11. [PMID:16239218]
45. Pedarzani P, Mosbacher J, Rivard A, Cingolani LA, Oliver D, Stocker M, Adelman JP, Fakler B. (2001) Control of electrical activity in central neurons by modulating the gating of small conductance Ca2+-activated K+ channels. J Biol Chem, 276 (13): 9762-9. [PMID:11134030]
46. Qunies AM, Spitznagel BD, Du Y, David Weaver C, Emmitte KA. (2023) Design, synthesis, and biological evaluation of a novel series of 1,2,4-oxadiazole inhibitors of SLACK potassium channels: Identification of in vitro tool VU0935685. Bioorg Med Chem, 95: 117487. [PMID:37812884]
47. Qunies AM, Spitznagel BD, Du Y, Peprah PK, Mohamed YK, Weaver CD, Emmitte KA. (2024) Structure-Activity Relationship Studies in a Series of Xanthine Inhibitors of SLACK Potassium Channels. Molecules, 29 (11). [PMID:38893312]
48. Romi-Lebrun R, Lebrun B, Martin-Eauclaire MF, Ishiguro M, Escoubas P, Wu FQ, Hisada M, Pongs O, Nakajima T. (1997) Purification, characterization, and synthesis of three novel toxins from the Chinese scorpion Buthus martensi, which act on K+ channels. Biochemistry, 36 (44): 13473-82. [PMID:9354615]
49. Romine JL, Martin SW, Meanwell NA, Gribkoff VK, Boissard CG, Dworetzky SI, Natale J, Moon S, Ortiz A, Yeleswaram S et al.. (2007) 3-[(5-Chloro-2-hydroxyphenyl)methyl]-5-[4-(trifluoromethyl)phenyl ]-1,3,4-oxadiazol-2(3H)-one, BMS-191011: opener of large-conductance Ca(2+)-activated potassium (maxi-K) channels, identification, solubility, and SAR. J Med Chem, 50 (3): 528-42. [PMID:17266205]
50. Roy S, Large RJ, Akande AM, Kshatri A, Webb TI, Domene C, Sergeant GP, McHale NG, Thornbury KD, Hollywood MA. (2014) Development of GoSlo-SR-5-69, a potent activator of large conductance Ca2+-activated K+ (BK) channels. Eur J Med Chem, 75: 426-37. [PMID:24561672]
51. Sanchez M, McManus OB. (1996) Paxilline inhibition of the alpha-subunit of the high-conductance calcium-activated potassium channel. Neuropharmacology, 35 (7): 963-8. [PMID:8938726]
52. Shah M, Haylett DG. (2000) The pharmacology of hSK1 Ca2+-activated K+ channels expressed in mammalian cell lines. Br J Pharmacol, 129 (4): 627-30. [PMID:10683185]
53. Shakkottai VG, Regaya I, Wulff H, Fajloun Z, Tomita H, Fathallah M, Cahalan MD, Gargus JJ, Sabatier JM, Chandy KG. (2001) Design and characterization of a highly selective peptide inhibitor of the small conductance calcium-activated K+ channel, SkCa2. J Biol Chem, 276 (46): 43145-51. [PMID:11527975]
54. Simó-Vicens R, Kirchhoff JE, Dolce B, Abildgaard L, Speerschneider T, Sørensen US, Grunnet M, Diness JG, Bentzen BH. (2017) A new negative allosteric modulator, AP14145, for the study of small conductance calcium-activated potassium (KCa 2) channels. Br J Pharmacol, 174 (23): 4396-4408. [PMID:28925012]
55. Stocker JW, De Franceschi L, McNaughton-Smith GA, Corrocher R, Beuzard Y, Brugnara C. (2003) ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. Blood, 101 (6): 2412-8. [PMID:12433690]
56. Stocker M, Hirzel K, D'hoedt D, Pedarzani P. (2004) Matching molecules to function: neuronal Ca2+-activated K+ channels and afterhyperpolarizations. Toxicon, 43 (8): 933-49. [PMID:15208027]
57. Strøbaek D, Hougaard C, Johansen TH, Sørensen US, Nielsen EØ, Nielsen KS, Taylor RD, Pedarzani P, Christophersen P. (2006) Inhibitory gating modulation of small conductance Ca2+-activated K+ channels by the synthetic compound (R)-N-(benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphtylamine (NS8593) reduces afterhyperpolarizing current in hippocampal CA1 neurons. Mol Pharmacol, 70 (5): 1771-82. [PMID:16926279]
58. Strøbaek D, Jørgensen TD, Christophersen P, Ahring PK, Olesen SP. (2000) Pharmacological characterization of small-conductance Ca(2+)-activated K(+) channels stably expressed in HEK 293 cells. Br J Pharmacol, 129 (5): 991-9. [PMID:10696100]
59. Strøbaek D, Teuber L, Jørgensen TD, Ahring PK, Kjaer K, Hansen RS, Olesen SP, Christophersen P, Skaaning-Jensen B. (2004) Activation of human IK and SK Ca2+ -activated K+ channels by NS309 (6,7-dichloro-1H-indole-2,3-dione 3-oxime). Biochim Biophys Acta, 1665 (1-2): 1-5. [PMID:15471565]
60. Strøbæk D, Brown DT, Jenkins DP, Chen YJ, Coleman N, Ando Y, Chiu P, Jørgensen S, Demnitz J, Wulff H et al.. (2013) NS6180, a new K(Ca) 3.1 channel inhibitor prevents T-cell activation and inflammation in a rat model of inflammatory bowel disease. Br J Pharmacol, 168 (2): 432-44. [PMID:22891655]
61. Syme CA, Gerlach AC, Singh AK, Devor DC. (2000) Pharmacological activation of cloned intermediate- and small-conductance Ca(2+)-activated K(+) channels. Am J Physiol, Cell Physiol, 278 (3): C570-81. [PMID:10712246]
62. Tang QY, Zhang Z, Xia XM, Lingle CJ. (2010) Block of mouse Slo1 and Slo3 K+ channels by CTX, IbTX, TEA, 4-AP and quinidine. Channels (Austin), 4 (1): 22-41. [PMID:19934650]
63. Tao J, Zhou ZL, Wu B, Shi J, Chen XM, Ji YH. (2014) Recombinant expression and functional characterization of martentoxin: a selective inhibitor for BK channel (α + β4). Toxins (Basel), 6 (4): 1419-33. [PMID:24759175]
64. Teramoto N, Brading AF, Ito Y. (2003) Multiple effects of mefenamic acid on K(+) currents in smooth muscle cells from pig proximal urethra. Br J Pharmacol, 140 (8): 1341-50. [PMID:14623761]
65. Wang G, Lemos JR. (1992) Tetrandrine blocks a slow, large-conductance, Ca(2+)-activated potassium channel besides inhibiting a non-inactivating Ca2+ current in isolated nerve terminals of the rat neurohypophysis. Pflugers Arch, 421 (6): 558-65. [PMID:1331975]
66. Wang J, Shen B, Guo M, Lou X, Duan Y, Cheng XP, Teng M, Niu L, Liu Q, Huang Q et al.. (2005) Blocking effect and crystal structure of natrin toxin, a cysteine-rich secretory protein from Naja atra venom that targets the BKCa channel. Biochemistry, 44 (30): 10145-52. [PMID:16042391]
67. Wang RX, Chai Q, Lu T, Lee HC. (2011) Activation of vascular BK channels by docosahexaenoic acid is dependent on cytochrome P450 epoxygenase activity. Cardiovasc Res, 90 (2): 344-52. [PMID:21187320]
68. Weatherall KL, Goodchild SJ, Jane DE, Marrion NV. (2010) Small conductance calcium-activated potassium channels: from structure to function. Prog Neurobiol, 91 (3): 242-55. [PMID:20359520]
69. Wittekindt OH, Visan V, Tomita H, Imtiaz F, Gargus JJ, Lehmann-Horn F, Grissmer S, Morris-Rosendahl DJ. (2004) An apamin- and scyllatoxin-insensitive isoform of the human SK3 channel. Mol Pharmacol, 65 (3): 788-801. [PMID:14978258]
70. Wrighton DC, Muench SP, Lippiat JD. (2015) Mechanism of inhibition of mouse Slo3 (KCa 5.1) potassium channels by quinine, quinidine and barium. Br J Pharmacol, 172 (17): 4355-63. [PMID:26045093]
71. Wu SN, Chen CC, Li HF, Lo YK, Chen SA, Chiang HT. (2002) Stimulation of the BK(Ca) channel in cultured smooth muscle cells of human trachea by magnolol. Thorax, 57 (1): 67-74. [PMID:11809993]
72. Wu SN, Li HF, Jan CR, Shen AY. (1999) Inhibition of Ca2+-activated K+ current by clotrimazole in rat anterior pituitary GH3 cells. Neuropharmacology, 38 (7): 979-89. [PMID:10428416]
73. Wulff H, Miller MJ, Hansel W, Grissmer S, Cahalan MD, Chandy KG. (2000) Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant. Proc Natl Acad Sci USA, 97 (14): 8151-6. [PMID:10884437]
74. Yang B, Gribkoff VK, Pan J, Damagnez V, Dworetzky SI, Boissard CG, Bhattacharjee A, Yan Y, Sigworth FJ, Kaczmarek LK. (2006) Pharmacological activation and inhibition of Slack (Slo2.2) channels. Neuropharmacology, 51 (4): 896-906. [PMID:16876206]
75. Yao J, Chen X, Li H, Zhou Y, Yao L, Wu G, Chen X, Zhang N, Zhou Z, Xu T et al.. (2005) BmP09, a "long chain" scorpion peptide blocker of BK channels. J Biol Chem, 280 (15): 14819-28. [PMID:15695820]
76. Zhang G, Xu X, Jia Z, Geng Y, Liang H, Shi J, Marras M, Abella C, Magleby KL, Silva JR et al.. (2022) An allosteric modulator activates BK channels by perturbing coupling between Ca2+ binding and pore opening. Nat Commun, 13 (1): 6784. [PMID:36351900]
77. Zhang M, Nam YW, Ramanishka A, Xu Y, Yasuda RM, Im D, Cui M, Chandy G, Wulff H. (2025) Structural basis for the subtype-selectivity of KCa2.2 channel activators. Res Sq, Preprint. [PMID:40470184]
NC-IUPHAR subcommittee and family contributors
Subcommittee members:
Leonard K. Kaczmarek (Chairperson)
Richard Aldrich
K. George Chandy
Stephan Grissmer
Aguan D. Wei
Heike Wulff |
Other contributors:
George A. Gutman |
How to cite this family page
Database page citation (select format):
Concise Guide to PHARMACOLOGY citation:
Alexander SPH, Striessnig J, Gibb AJ, Mathie AA, Veale EL, Kelly E, Peach CJ, Armstrong JF, Faccenda E, Harding SD, Southan C, Davies JA et al. (2025) The Concise Guide to PHARMACOLOGY 2025/26: Ion channels. Br J Pharmacol. 182: S152-S241.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License